top of page

Search

Muvon
Apr 162 min read
MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025
Zurich, Switzerland, April 16, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the...
Â
Â

Muvon
Jul 30, 20242 min read
Â
Â

Muvon
Dec 7, 20231 min read
Â
Â

Muvon
Jun 12, 20231 min read
Â
Â

Muvon
Jun 2, 20231 min read
Â
Â

Muvon
Apr 24, 20231 min read
Â
Â

Muvon
Dec 22, 20221 min read
Â
Â

Muvon
Nov 16, 20223 min read
Â
Â
INVEST IN OUR
INNOVATION
Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.
bottom of page